COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.
New investigational drug for advanced or metastatic solid tumor cancers
Darren Sigal, M.D.
The purpose of this open label study is to test the safety and effectiveness of OBI-888 (investigational study drug), given weekly via intravenous infusion (IV), in patients with locally advanced or metastatic solid tumor cancer.
Be 18 yrs of age or older
Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light house work, or office work.
Have a tissue specimen from a prior biopsy or recent biopsy to be submitted for Globo H analysis
Patients must not:
Be pregnant or nursing
Have an active autoimmune or inflammatory disease requiring systemic treatment within the past 2Months, or autoimmune disease that requires systemic steroids or other immunosuppressive medications
Have a history of solid organ transplant
Have known untreated central nervous system disease
All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (La Jolla).
Study treatment is given weekly by intravenous infusion (IV).
Search for NCT03573544 on https://clinicaltrials.gov/ for additional information.